Diabetes drugs may reverse fatty liver damage in new trial
Disease control
Completed
This study tests whether combining two diabetes drugs—semaglutide and empagliflozin—can reverse liver damage from NASH (a severe form of fatty liver disease) in people with type 2 diabetes. Participants will receive either the combo, empagliflozin alone, or a placebo for 48 weeks…
Phase: PHASE4 • Sponsor: German Diabetes Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC